Evidence map›Paper›PMID 42418465›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease.

Abhay R Moghekar, James A Rock, Richard C Mohs, Oskar Hansson, Erik Stomrud, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Sterling C Johnson, Henrik Zetterberg, Rachel R Radwan and 8 more

Abstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Abhay R MoghekarDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
James A RockAriBio Co., Ltd, San Diego, California, USA.
Richard C MohsGlobal Alzheimer's Platform Foundation, Washington, District of Columbia, USA.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Sebastian PalmqvistClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Niklas Mattsson-CarlgrenClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Sterling C JohnsonWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Henrik ZetterbergWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Rachel R RadwanFujirebio Diagnostics, Inc., Malvern, Pennsylvania, USA.
Jessica JunfolaFujirebio Diagnostics, Inc., Malvern, Pennsylvania, USA.
M Craig MillerFujirebio Diagnostics, Inc., Malvern, Pennsylvania, USA.
Luna BuitragoFujirebio Diagnostics, Inc., Malvern, Pennsylvania, USA.
Francesca I De SimoneFujirebio Diagnostics, Inc., Malvern, Pennsylvania, USA.
Katie MartinFujirebio Diagnostics, Inc., Malvern, Pennsylvania, USA.
Diana DicksonFujirebio Diagnostics, Inc., Malvern, Pennsylvania, USA.
Natalya BeninaFujirebio Diagnostics, Inc., Malvern, Pennsylvania, USA.
Douglas M HawkinsSchool of Statistics, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

Prospective validation and implementation of high-performing blood biomarkers and digital cognitive tests for detection of Alzheimer's disease in specialist memory clinic and primary care settingsR01AG083740 · NIA · LUNDS UNIVERSITET · PI Sebastian Palmqvist · 2023 to 2026
$1.9M
Alzheimer's Association SG-23-1061717Alzheimer's Drug Discovery Foundation (ADDF)Bundy AcademyFamily Rönström FRS-0004Family Rönström FRS-0011Foundation for the National Institutes of Health AG062715Fujirebio USKamprad Foundation 20243058MultiPark at Lund UniversityNational Institutes of Health (NIH)NIA NIH HHS P30-AG005146NIA NIH HHS R01AG083740NIA NIH HHS U19-AG033655Swedish Alzheimer Foundation AF-1011949Swedish Brain Foundation FO2024-0284Wisconsin Alzheimer's Disease Research Center (WADRC)Wisconsin Registry for Alzheimer's Prevention (WRAP) AG021155Wisconsin Registry for Alzheimer's Prevention (WRAP) AG027161
6 · The paper itself

Abstract

introductionThis study evaluated the diagnostic performance of the Lumipulse

methodsThe Lumipulse Plasma Ratio was evaluated using predetermined thresholds (≤0.00370 negative; ≥0.00738 positive) against cerebrospinal fluid (CSF) biomarker ratios or amyloid positron emission tomography (PET) imaging as references in 499 adults (≥50 years old) enrolled in prospective studies conducted across academic memory clinics and research centers.

resultsAmyloid status was determined by CSF in 347 patients (189 positive [54.5%]) and by PET imaging in 152 patients (66 positive [43.4%]). The Lumipulse Plasma Ratio was positive in 219 patients (43.9%), negative in 182 (36.5%), and indeterminate in 98 (19.6%). Positive and negative predictive values were 91.8% and 97.3%, with a sensitivity and specificity of 97.6% and 90.8%, respectively. DISCUSSION: The US Food and Drug Administration-cleared Lumipulse Plasma Ratio demonstrated high accuracy in identifying amyloid pathology and offers an alternative to CSF testing and amyloid PET imaging.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesPeptide Fragmentstau ProteinsAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPositron-Emission TomographySensitivity and SpecificityAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseaseamyloid pathologyblood‐based biomarkersFujirebioLumipulsephosphorylated tau 217/amyloid beta 1‐42 plasma ratiop‐tau217/Aβ1‐42

Identifiers

PMID42418465
PMCPMC13344886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.